{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T14:24:11Z","timestamp":1780496651453,"version":"3.54.1"},"reference-count":66,"publisher":"Pharmaceutical Society of Japan","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological & Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2025,7,1]]},"DOI":"10.1248\/bpb.b25-00063","type":"journal-article","created":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T22:10:43Z","timestamp":1751321443000},"page":"957-965","source":"Crossref","is-referenced-by-count":1,"title":["Clinical Applications of Cell-Specific Carriers Based on Glycosylated Albumin"],"prefix":"10.1248","volume":"48","author":[{"given":"Hitoshi","family":"Maeda","sequence":"first","affiliation":[{"name":"Department of Biopharmaceutics, Graduate School of Pharmaceutical Sciences, Kumamoto University"},{"name":"Laboratory of Biopharmaceutics, Kyoto Pharmaceutical University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1) Chan MWY, Viswanathan S. Recent progress on developing exogenous monocyte\/macrophage-based therapies for inflammatory and degenerative diseases. Cytotherapy<\/i>, 21<\/b>, 393\u2013415 (2019).","DOI":"10.1016\/j.jcyt.2019.02.002"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2) McAnulty RJ. Fibroblasts and myofibroblasts: their source, function and role in disease. Int. J. Biochem. Cell Biol.<\/i>, 39<\/b>, 666\u2013671 (2007).","DOI":"10.1016\/j.biocel.2006.11.005"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3) Gordon S. Alternative activation of macrophages. Nat. Rev. Immunol.<\/i>, 3<\/b>, 23\u201335 (2003).","DOI":"10.1038\/nri978"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4) Kalluri R, Zeisberg M. Fibroblasts in cancer. Nat. Rev. Cancer<\/i>, 6<\/b>, 392\u2013401 (2006).","DOI":"10.1038\/nrc1877"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Sheikh H, Yarwood H, Ashworth A, Isacke CM. Endo180, an endocytic recycling glycoprotein related to the macrophage mannose receptor is expressed on fibroblasts, endothelial cells and macrophages and functions as a lectin receptor. J. Cell Sci.<\/i>, 113<\/b>, 1021\u20131032 (2000).","DOI":"10.1242\/jcs.113.6.1021"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Boskovic J, Arnold JN, Stilion R, Gordon S, Sim RB, Rivera-Calzada A, Wienke D, Isacke CM, Martinez-Pomares L, Llorca O. Structural model for the mannose receptor family uncovered by electron microscopy of Endo180 and the mannose receptor. J. Biol. Chem.<\/i>, 281<\/b>, 8780\u20138787 (2006).","DOI":"10.1074\/jbc.M513277200"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7) Fanali G, di Masi A, Trezza V, Marino M, Fasano M, Ascenzi P. Human serum albumin: from bench to bedside. Mol. Aspects Med.<\/i>, 33<\/b>, 209\u2013290 (2012).","DOI":"10.1016\/j.mam.2011.12.002"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8) Lombardi S, Aaen KH, Nilsen J, Ferrarese M, Gj\u00f8lberg TT, Bernardi F, Pinotti M, Andersen JT, Branchini A. Fusion of engineered albumin with factor IX Padua extends half-life and improves coagulant activity. Br. J. Haematol.<\/i>, 194<\/b>, 453\u2013462 (2021).","DOI":"10.1111\/bjh.17559"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9) Fu Q, Sun J, Zhang W, Sui X, Yan Z, He Z. Nanoparticle albumin-bound (NAB) technology is a promising method for anti-cancer drug delivery. Recent Pat. Anticancer Drug Discov.<\/i>, 4<\/b>, 262\u2013272 (2009).","DOI":"10.2174\/157489209789206869"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10) Carlson J, Sakamoto Y, Laurell CB, Madison J, Watkins S, Putnam FW. Alloalbuminemia in Sweden: structural study and phenotypic distribution of nine albumin variants. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 89<\/b>, 8225\u20138229 (1992).","DOI":"10.1073\/pnas.89.17.8225"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11) Brennan SO, Rollo C, Potter HC. Novel silent albumin variant (191Ala\u2192Thr) detected by TOF MS of whole plasma. Clin. Chim. Acta<\/i>, 440<\/b>, 40\u201343 (2015).","DOI":"10.1016\/j.cca.2014.11.003"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12) Brennan SO, Myles T, Peach RJ, Donaldson D, George PM. Albumin Redhill (\u22121 Arg, 320 Ala\u2192Thr): a glycoprotein variant of human serum albumin whose precursor has an aberrant signal peptidase cleavage site. Proc. Natl. Acad. Sci. U.S.A.<\/i>, 87<\/b>, 26\u201330 (1990).","DOI":"10.1073\/pnas.87.1.26"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13) Peach RJ, Brennan SO. Structural characterization of a glycoprotein variant of human serum albumin: albumin Casebrook (494Asp\u2192Asn). Biochim. Biophys. Acta Mol. Basis Dis.<\/i>, 1097<\/b>, 49\u201354 (1991).","DOI":"10.1016\/0925-4439(91)90023-3"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Peters T Jr. All about albumin: biochemistry, genetics, and medical applications<\/i>. Academic press, Cambridge, MA (1995).","DOI":"10.1016\/B978-012552110-9\/50006-4"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15) McGreal EP, Rosas M, Brown GD, Zamze S, Wong SY, Gordon S, Martinez-Pomares L, Taylor PR. The carbohydrate-recognition domain of Dectin-2 is a C-type lectin with specificity for high mannose. Glycobiology<\/i>, 16<\/b>, 422\u2013430 (2006).","DOI":"10.1093\/glycob\/cwj077"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16) Taylor ME, Drickamer K. Introduction to glycobiology<\/i>. Oxford university press, Oxford, U.K. (2011).","DOI":"10.1093\/hesc\/9780199569113.001.0001"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17) Hirata K, Maruyama T, Watanabe H, Maeda H, Nakajou K, Iwao Y, Ishima Y, Katsumi H, Hashida M, Otagiri M. Genetically engineered mannosylated-human serum albumin as a versatile carrier for liver-selective therapeutics. J. Control. Release<\/i>, 145<\/b>, 9\u201316 (2010).","DOI":"10.1016\/j.jconrel.2010.03.010"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18) Kogelberg H, Tolner B, Sharma SK, Lowdell MW, Qureshi U, Robson M, Hillyer T, Pedley RB, Vervecken W, Contreras R, Begent RH, Chester KA. Clearance mechanism of a mannosylated antibody-enzyme fusion protein used in experimental cancer therapy. Glycobiology<\/i>, 17<\/b>, 36\u201345 (2007).","DOI":"10.1093\/glycob\/cwl053"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19) Roberts RA, Ganey PE, Ju C, Kamendulis LM, Rusyn I, Klaunig JE. Role of the Kupffer cell in mediating hepatic toxicity and carcinogenesis. Toxicol. Sci.<\/i>, 96<\/b>, 2\u201315 (2007).","DOI":"10.1093\/toxsci\/kfl173"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20) Jaeschke H. Reactive oxygen and mechanisms of inflammatory liver injury: present concepts. J. Gastroenterol. Hepatol.<\/i>, 26<\/b> (Suppl. 1), 173\u2013179 (2011).","DOI":"10.1111\/j.1440-1746.2010.06592.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Maeda H, Hirata K, Watanabe H, Ishima Y, Chuang VT, Taguchi K, Inatsu A, Kinoshita M, Tanaka M, Sasaki Y, Otagiri M, Maruyama T. Polythiol-containing, recombinant mannosylated-albumin is a superior CD68+\/CD206+ Kupffer cell-targeted nanoantioxidant for treatment of two acute hepatitis models. J. Pharmacol. Exp. Ther.<\/i>, 352<\/b>, 244\u2013257 (2015).","DOI":"10.1124\/jpet.114.219493"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22) Nakashima H, Kinoshita M, Nakashima M, Habu Y, Shono S, Uchida T, Shinomiya N, Seki S. Superoxide produced by Kupffer cells is an essential effector in concanavalin A-induced hepatitis in mice. Hepatology<\/i>, 48<\/b>, 1979\u20131988 (2008).","DOI":"10.1002\/hep.22561"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Maeda H, Minayoshi Y, Ichimizu S, Mizuta Y, Nagasaki T, Matsusaka K, Oshiro S, Oniki K, Saruwatari J, Ishima Y, Watanabe H, Otagiri M, Maruyama T. Repeated administration of kupffer cells-targeting nanoantioxidant ameliorates liver fibrosis in an experimental mouse model. Biol. Pharm. Bull.<\/i>, 43<\/b>, 93\u2013101 (2020).","DOI":"10.1248\/bpb.b19-00599"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24) Maeda H, Ishima Y, Saruwatari J, et al.<\/i> Nitric oxide facilitates the targeting Kupffer cells of a nano-antioxidant for the treatment of NASH. J. Control. Release<\/i>, 341<\/b>, 457\u2013474 (2022).","DOI":"10.1016\/j.jconrel.2021.11.039"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25) Tilg H, Kaser A, Moschen AR. How to modulate inflammatory cytokines in liver diseases. Liver Int.<\/i>, 26<\/b>, 1029\u20131039 (2006).","DOI":"10.1111\/j.1478-3231.2006.01339.x"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Albano E, Vidali M. Immune mechanisms in alcoholic liver disease. Genes Nutr.<\/i>, 5<\/b>, 141\u2013147 (2010).","DOI":"10.1007\/s12263-009-0151-4"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27) Bieghs V, Trautwein C. The innate immune response during liver inflammation and metabolic disease. Trends Immunol.<\/i>, 34<\/b>, 446\u2013452 (2013).","DOI":"10.1016\/j.it.2013.04.005"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28) Friedman RM. Clinical uses of interferons. Br. J. Clin. Pharmacol.<\/i>, 65<\/b>, 158\u2013162 (2008).","DOI":"10.1111\/j.1365-2125.2007.03055.x"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29) Ivashkiv LB, Donlin LT. Regulation of type I interferon responses. Nat. Rev. Immunol.<\/i>, 14<\/b>, 36\u201349 (2014).","DOI":"10.1038\/nri3581"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30) Ziegler-Heitbrock L, L\u00f6tzerich M, Schaefer A, Werner T, Frankenberger M, Benkhart E. IFN-\u03b1 induces the human IL-10 gene by recruiting both IFN regulatory factor 1 and Stat3. J. Immunol.<\/i>, 171<\/b>, 285\u2013290 (2003).","DOI":"10.4049\/jimmunol.171.1.285"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31) Guarda G, Braun M, Staehli F, Tardivel A, Mattmann C, F\u00f6rster I, Farlik M, Decker T, Du Pasquier RA, Romero P, Tschopp J. Type I Interferon inhibits interleukin-1 production and inflammasome activation. Immunity<\/i>, 34<\/b>, 213\u2013223 (2011).","DOI":"10.1016\/j.immuni.2011.02.006"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32) Petrasek J, Dolganiuc A, Csak T, Nath B, Hritz I, Kodys K, Catalano D, Kurt-Jones E, Mandrekar P, Szabo G. Interferon regulatory factor 3 and type I interferons are protective in alcoholic liver injury in mice by way of crosstalk of parenchymal and myeloid cells. Hepatology<\/i>, 53<\/b>, 649\u2013660 (2011).","DOI":"10.1002\/hep.24059"},{"key":"33","doi-asserted-by":"crossref","unstructured":"33) Roh YS, Park S, Kim JW, Lim CW, Seki E, Kim B. Toll-like receptor 7-mediated type I interferon signaling prevents cholestasis- and hepatotoxin-induced liver fibrosis. Hepatology<\/i>, 60<\/b>, 237\u2013249 (2014).","DOI":"10.1002\/hep.26981"},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Petrasek J, Bala S, Csak T, Lippai D, Kodys K, Menashy V, Barrieau M, Min SY, Kurt-Jones EA, Szabo G. IL-1 receptor antagonist ameliorates inflammasome-dependent alcoholic steatohepatitis in mice. J. Clin. Invest.<\/i>, 122<\/b>, 3476\u20133489 (2012).","DOI":"10.1172\/JCI60777"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Minayoshi Y, Maeda H, Yanagisawa H, et al.<\/i> Development of Kupffer cell targeting type-I interferon for the treatment of hepatitis via<\/i> inducing anti-inflammatory and immunomodulatory actions. Drug Deliv.<\/i>, 25<\/b>, 1067\u20131077 (2018).","DOI":"10.1080\/10717544.2018.1464083"},{"key":"36","doi-asserted-by":"crossref","unstructured":"36) Minayoshi Y, Maeda H, Hamasaki K, Nagasaki T, Takano M, Fukuda R, Mizuta Y, Tanaka M, Sasaki Y, Otagiri M, Watanabe H, Maruyama T. Mouse type-I interferon-mannosylated albumin fusion protein for the treatment of chronic hepatitis. Pharmaceuticals <\/i>(Basel), 17<\/b>, 260 (2024).","DOI":"10.3390\/ph17020260"},{"key":"37","doi-asserted-by":"crossref","unstructured":"37) Hosein AN, Brekken RA, Maitra A. Pancreatic cancer stroma: an update on therapeutic targeting strategies. Nat. Rev. Gastroenterol. Hepatol.<\/i>, 17<\/b>, 487\u2013505 (2020).","DOI":"10.1038\/s41575-020-0300-1"},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Zhou Z, Lu ZR. Molecular imaging of the tumor microenvironment. Adv. Drug Deliv. Rev.<\/i>, 113<\/b>, 24\u201348 (2017).","DOI":"10.1016\/j.addr.2016.07.012"},{"key":"39","doi-asserted-by":"crossref","unstructured":"39) Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell<\/i>, 144<\/b>, 646\u2013674 (2011).","DOI":"10.1016\/j.cell.2011.02.013"},{"key":"40","doi-asserted-by":"crossref","unstructured":"40) Quail DF, Joyce JA. Microenvironmental regulation of tumor progression and metastasis. Nat. Med.<\/i>, 19<\/b>, 1423\u20131437 (2013).","DOI":"10.1038\/nm.3394"},{"key":"41","doi-asserted-by":"crossref","unstructured":"41) Balkwill FR, Capasso M, Hagemann T. The tumor microenvironment at a glance. J. Cell Sci.<\/i>, 125<\/b>, 5591\u20135596 (2012).","DOI":"10.1242\/jcs.116392"},{"key":"42","doi-asserted-by":"crossref","unstructured":"42) Nii T, Makino K, Tabata Y. Three-dimensional culture system of cancer cells combined with biomaterials for drug screening. Cancers<\/i> (Basel), 12<\/b>, 2754 (2020).","DOI":"10.3390\/cancers12102754"},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Kumar MP, Du J, Lagoudas G, Jiao Y, Sawyer A, Drummond DC, Lauffenburger DA, Raue A. Analysis of single-cell RNA-Seq identifies cell\u2013cell communication associated with tumor characteristics. Cell Rep.<\/i>, 25<\/b>, 1458\u20131468.e4 (2018).","DOI":"10.1016\/j.celrep.2018.10.047"},{"key":"44","doi-asserted-by":"crossref","unstructured":"44) Datta M, Coussens LM, Nishikawa H, Hodi FS, Jain RK. Reprogramming the tumor microenvironment to improve immunotherapy: emerging strategies and combination therapies. Am. Soc. Clin. Oncol. Educ. Book<\/i>, 39<\/b>, 165\u2013174 (2019).","DOI":"10.1200\/EDBK_237987"},{"key":"45","doi-asserted-by":"crossref","unstructured":"45) Baghban R, Roshangar L, Jahanban-Esfahlan R, Seidi K, Ebrahimi-Kalan A, Jaymand M, Kolahian S, Javaheri T, Zare P. Tumor microenvironment complexity and therapeutic implications at a glance. Cell Commun. Signal.<\/i>, 18<\/b>, 59 (2020).","DOI":"10.1186\/s12964-020-0530-4"},{"key":"46","doi-asserted-by":"crossref","unstructured":"46) Chen Q, Liu G, Liu S, Su H, Wang Y, Li J, Luo C. Remodeling the tumor microenvironment with emerging nanotherapeutics. Trends Pharmacol. Sci.<\/i>, 39<\/b>, 59\u201374 (2018).","DOI":"10.1016\/j.tips.2017.10.009"},{"key":"47","doi-asserted-by":"crossref","unstructured":"47) Knop K, Hoogenboom R, Fischer D, Schubert US. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew. Chem. Int. Ed.<\/i>, 49<\/b>, 6288\u20136308 (2010).","DOI":"10.1002\/anie.200902672"},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Dhalluin C, Ross A, Huber W, Gerber P, Brugger D, Gsell B, Senn H. Structural, kinetic, and thermodynamic analysis of the binding of the 40\u2009kDa PEG-interferon-alpha2a and its individual positional isomers to the extracellular domain of the receptor IFNAR2. Bioconjug. Chem.<\/i>, 16<\/b>, 518\u2013527 (2005).","DOI":"10.1021\/bc049780h"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Mehtala JG, Kulczar C, Lavan M, Knipp G, Wei A. Cys34-PEGylated human serum albumin for drug binding and delivery. Bioconjug. Chem.<\/i>, 26<\/b>, 941\u2013949 (2015).","DOI":"10.1021\/acs.bioconjchem.5b00143"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Zhao T, Cheng YN, Tan HN, Liu JF, Xu HL, Pang GL, Wang FS. Site-specific chemical modification of human serum albumin with polyethylene glycol prolongs half-life and improves intravascular retention in mice. Biol. Pharm. Bull.<\/i>, 35<\/b>, 280\u2013288 (2012).","DOI":"10.1248\/bpb.35.280"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Grenier P, Viana IMO, Lima EM, Bertrand N. Anti-polyethylene glycol antibodies alter the protein corona deposited on nanoparticles and the physiological pathways regulating their fate in vivo.<\/i> J. Control. Release<\/i>, 287<\/b>, 121\u2013131 (2018).","DOI":"10.1016\/j.jconrel.2018.08.022"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Paris G, Kraszewski S, Ramseyer C, Enescu M. About the structural role of disulfide bridges in serum albumins: evidence from protein simulated unfolding. Biopolymers<\/i>, 97<\/b>, 889\u2013898 (2012).","DOI":"10.1002\/bip.22096"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Bocedi A, Cattani G, Stella L, Massoud R, Ricci G. Thiol disulfide exchange reactions in human serum albumin: the apparent paradox of the redox transitions of Cys. FEBS J.<\/i>, 285<\/b>, 3225\u20133237 (2018).","DOI":"10.1111\/febs.14609"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Nakashima F, Shibata T, Kamiya K, Yoshitake J, Kikuchi R, Matsushita T, Ishii I, Gim\u00e9nez-Bastida JA, Schneider C, Uchida K. Structural and functional insights into S<\/i>-thiolation of human serum albumins. Sci. Rep.<\/i>, 8<\/b>, 932 (2018).","DOI":"10.1038\/s41598-018-19610-9"},{"key":"55","doi-asserted-by":"crossref","unstructured":"55) Mizuta Y, Maeda H, Ishima Y, Minayoshi Y, Ichimizu S, Kinoshita R, Fujita I, Kai T, Hirata K, Nakamura T, Saruwatari J, Arima H, Watanabe H, Otagiri M, Maruyama T. A mannosylated, pegylated albumin as a drug delivery system for the treatment of cancer stroma cells. Adv. Funct. Mater.<\/i>, 31<\/b>, 2104136 (2021).","DOI":"10.1002\/adfm.202104136"},{"key":"56","doi-asserted-by":"crossref","unstructured":"56) Sch\u00fctz CA, Juillerat-Jeanneret L, Mueller H, Lynch I, Riediker M. Therapeutic nanoparticles in clinics and under clinical evaluation. Nanomedicine<\/i> (Lond.), 8<\/b>, 449\u2013467 (2013).","DOI":"10.2217\/nnm.13.8"},{"key":"57","doi-asserted-by":"crossref","unstructured":"57) Gonzalez-Angulo AM, Meric-Bernstam F, Chawla S, Falchook G, Hong D, Akcakanat A, Chen H, Naing A, Fu S, Wheler J, Moulder S, Helgason T, Li S, Elias I, Desai N, Kurzrock R. Weekly nab<\/i>-Rapamycin in patients with advanced nonhematologic malignancies: final results of a phase I trial. Clin. Cancer Res.<\/i>, 19<\/b>, 5474\u20135484 (2013).","DOI":"10.1158\/1078-0432.CCR-12-3110"},{"key":"58","doi-asserted-by":"crossref","unstructured":"58) Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Des. Devel. Ther.<\/i>, 9<\/b>, 3767\u20133777 (2015).","DOI":"10.2147\/DDDT.S88023"},{"key":"59","doi-asserted-by":"crossref","unstructured":"59) Ferreira AK, Meneguelo R, Neto SC, Chierice GO, Maria DA. Synthetic phosphoethanolamine induces apoptosis through caspase-3 pathway by decreasing expression of Bax\/Bad protein and changes cellcycle in melanoma. J. Cancer Sci. Ther.<\/i>, 3<\/b>, 53\u201359 (2011).","DOI":"10.4172\/1948-5956.1000058"},{"key":"60","doi-asserted-by":"crossref","unstructured":"60) Varki A. Biological roles of glycans. Glycobiology<\/i>, 27<\/b>, 3\u201349 (2017).","DOI":"10.1093\/glycob\/cww086"},{"key":"61","doi-asserted-by":"crossref","unstructured":"61) Sun S, Hu Y, Ao M, Shah P, Chen J, Yang W, Jia X, Tian Y, Thomas S, Zhang H. N<\/i>-GlycositeAtlas: a database resource for mass spectrometry-based human N-linked glycoprotein and glycosylation site mapping. Clin. Proteomics<\/i>, 16<\/b>, 35 (2019).","DOI":"10.1186\/s12014-019-9254-0"},{"key":"62","doi-asserted-by":"crossref","unstructured":"62) Paurevi\u0107 M, \u0160rajer Gajdo\u0161ik M, Ribi\u0107 R. Mannose ligands for mannose receptor targeting. Int. J. Mol. Sci.<\/i>, 25<\/b>, 1370 (2024).","DOI":"10.3390\/ijms25031370"},{"key":"63","doi-asserted-by":"crossref","unstructured":"63) Cummings RD. The mannose receptor ligands and the macrophage glycome. Curr. Opin. Struct. Biol.<\/i>, 75<\/b>, 102394 (2022).","DOI":"10.1016\/j.sbi.2022.102394"},{"key":"64","doi-asserted-by":"crossref","unstructured":"64) Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, Sussman JL, Savickas PJ, Robinson GS, Futerman AH. Characterization of gene-activated human acid-beta-glucosidase: crystal structure, glycan composition, and internalization into macrophages. Glycobiology<\/i>, 20<\/b>, 24\u201332 (2010).","DOI":"10.1093\/glycob\/cwp138"},{"key":"65","doi-asserted-by":"crossref","unstructured":"65) Ghuman J, Zunszain PA, Petitpas I, Bhattacharya AA, Otagiri M, Curry S. Structural basis of the drug-binding specificity of human serum albumin. J. Mol. Biol.<\/i>, 353<\/b>, 38\u201352 (2005).","DOI":"10.1016\/j.jmb.2005.07.075"},{"key":"66","doi-asserted-by":"crossref","unstructured":"66) Maeda H. Albumin-based drug delivery system targeting mannose receptors and its application to medical treatments. Yakugaku Zasshi<\/i>, 143<\/b>, 923\u2013930 (2023).","DOI":"10.1248\/yakushi.23-00118"}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00063\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,5]],"date-time":"2025-07-05T03:46:32Z","timestamp":1751687192000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/48\/7\/48_b25-00063\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":66,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b25-00063","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,1]]},"article-number":"b25-00063"}}